A61K 38/1866
Vascular endothelial growth factor [vegf]
Official title: {Vascular endothelial growth factor [VEGF]}
A61K38/1866 (Vascular endothelial growth factor [vegf]) appears on 593 US grants and 1,199 published applications in this corpus.
Search patents in A61K- Granted patents
- 593
- Published applications
- 1,199
- Assignees
- 528
- Inventors
- 1,810
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 5 | 4 |
| 2002 | 9 | 20 |
| 2003 | 2 | 36 |
| 2004 | 10 | 48 |
| 2005 | 12 | 45 |
| 2006 | 10 | 50 |
| 2007 | 19 | 46 |
| 2008 | 11 | 35 |
| 2009 | 21 | 34 |
| 2010 | 18 | 55 |
| 2011 | 18 | 47 |
| 2012 | 32 | 38 |
| 2013 | 24 | 56 |
| 2014 | 28 | 59 |
| 2015 | 31 | 90 |
| 2016 | 40 | 58 |
| 2017 | 44 | 55 |
| 2018 | 34 | 48 |
| 2019 | 32 | 63 |
| 2020 | 33 | 43 |
| 2021 | 34 | 58 |
| 2022 | 32 | 61 |
| 2023 | 26 | 42 |
| 2024 | 35 | 50 |
| 2025 | 17 | 38 |
| 2026 | 10 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Kidney-targeted drug delivery systems30 Jun 2026US 12,667,623 B2University of Mississippi Medical Center
- Tumor specific antibody conjugates and uses therefor21 Apr 2026US 12,605,469 B2OncoTAb, Inc.
- Allogeneic human plasma and platelet derived products and uses thereof17 Mar 2026US 12,576,109 B2Consano Bio, Inc.
- Bio-inspired tissue-adhesive hydrogel patch and uses thereof10 Mar 2026US 12,569,451 B2Cellartgen Inc.
- Combination grafts for tissue repair or regeneration applications10 Mar 2026US 12,569,593 B2Rejuvablast LLC
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308231 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308232 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308233 A1Regeneron Pharmaceuticals, Inc.
- Neurotrauma treatment1 Oct 2026US 2026/0295016 A1Ecole Polytechnique Federale De Lausanne (Epfl)
- Anti-vegf protein compositions and methods for producing the same24 Sep 2026US 2026/0285940 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins198US 9,303,079 B2Moderna Therapeutics, Inc. · 2016
- Methods of ophthalmic administration187US 6,378,526 B1Insite Vision Incorporated · 2002
- Treatment of vascular injury using vascular endothelial growth factor182US 5,830,879 ASt. Elizabeth's Medical Center of Boston, Inc. · 1998
- Treatment of retinitis pigmentosa with human umbilical cord cells175US 7,413,734 B2Ethicon, Inc. · 2008
- Localized intravascular delivery of growth factors for promotion of angiogenesis169US 5,941,868 ABeth Israel Deaconess Medical Center, Inc. · 1999